Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Developments
AMGN logo

Amgen Reports 10% Sales Growth Driven by 13% Volume Surge Amid Patent Expiries

AMGN10-KFiling Date: 2/13/2026
Amgen Inc.
Description

What this story covers

Amgen's 2025 10-K reveals a resilient 10% sales increase fueled by volume growth, offsetting pricing pressures and patent losses. Key highlights include a $10 billion operating cash flow, strategic obesity drug trials, and a significant $6 billion debt reduction.

Story snapshot

CompanyAmgen Inc.
TickerAMGN
VariantStandard detailed
Duration12:34
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000318154-26-000010
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in